Harbor Capital Advisors, Inc. Krystal Biotech, Inc. Transaction History

Harbor Capital Advisors, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$108.01 - $179.35 $161,474 - $268,128	1,495 Added 23.87%	7,757 $1.38 Million
Q4 2023 Jan 08, 2024	BUY	$96.0 - $128.29 $110,208 - $147,276	1,148 Added 22.45%	6,262 $776,000
Q3 2023 Oct 20, 2023	SELL	$108.51 - $130.22 $202,262 - $242,730	-1,864 Reduced 26.71%	5,114 $593,000
Q2 2023 Jul 11, 2023	BUY	$78.48 - $130.32 $46,695 - $77,540	595 Added 9.32%	6,978 $819,000
Q1 2023 Apr 26, 2023	SELL	$72.39 - $84.27 $153,322 - $178,483	-2,118 Reduced 24.91%	6,383 $511,000
Q4 2022 Jan 20, 2023	SELL	$63.14 - $79.9 $206,846 - $261,752	-3,276 Reduced 27.82%	8,501 $0
Q3 2022 Oct 28, 2022	SELL	$64.85 - $82.4 $82,813 - $105,224	-1,277 Reduced 9.78%	11,777 $821,000
Q2 2022 Jul 26, 2022	SELL	$48.93 - $73.47 $110,141 - $165,380	-2,251 Reduced 14.71%	13,054 $857,000
Q1 2022 Apr 28, 2022	SELL	$51.99 - $72.11 $164,652 - $228,372	-3,167 Reduced 17.14%	15,305 $1.02 Million
Q4 2021 Feb 04, 2022	BUY	$39.81 - $88.24 $735,370 - $1.63 Million	18,472 New	18,472 $1.29 Million

266

25M

270K

172K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.66B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.